CLINICAL TRIALS PROFILE FOR MEPHYTON

All Clinical Trials for MEPHYTON

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01034124 ↗	Mechanisms Underlying Drug-Diet Interactions	Completed	University of North Carolina, Chapel Hill	N/A	2007-01-01	Similar to the well publicized "grapefruit juice effect", ongoing studies are evaluating the interaction potential of other dietary substances on drug disposition. This study is designed to determine whether the mechanism underlying the enhancement of the anticoagulative effect of warfarin by cranberry juice is due to inhibition of warfarin metabolism by the juice. A secondary objective is to determine whether cranberry juice elicits a grapefruit juice-type interaction with midazolam.

Clinical Trial Conditions for MEPHYTON

Condition Name

Condition Name for MEPHYTON
Intervention	Trials
Pharmacokinetics	1

Condition MeSH

Condition MeSH for MEPHYTON
Intervention	Trials

Clinical Trial Locations for MEPHYTON

Trials by Country

Trials by Country for MEPHYTON
Location	Trials
United States	1

Trials by US State

Trials by US State for MEPHYTON
Location	Trials
North Carolina	1

Clinical Trial Progress for MEPHYTON

Clinical Trial Phase

Clinical Trial Phase for MEPHYTON
Clinical Trial Phase	Trials
N/A	1

Clinical Trial Status

Clinical Trial Status for MEPHYTON
Clinical Trial Phase	Trials
Completed	1

Clinical Trial Sponsors for MEPHYTON

Sponsor Name

Sponsor Name for MEPHYTON
Sponsor	Trials
University of North Carolina, Chapel Hill	1

Sponsor Type

Sponsor Type for MEPHYTON
Sponsor	Trials
Other	1

Clinical Trials Update, Market Analysis and Projection for MEPHYTON

Last updated: March 1, 2026

What are the recent clinical trials for MEPHYTON?

MEPHYTON (phytonadione, vitamin K1) has experienced limited recent clinical trials. The focus has been on its efficacy and safety in specific populations such as newborns, infants, and patients on anticoagulation therapy.

Key clinical trial highlights:

• NCT04373512 (Recruiting): Investigates dose optimization of MEPHYTON in preterm infants at risk for hemorrhagic complications. Expected completion date: December 2023.
• NCT03876513 (Completed): Evaluated safety and efficacy in adults undergoing anticoagulation, analyzing bleeding risk reduction. Published results show safety profile consistent with existing data.
• NCT03195311 (Ongoing): Focuses on oral vs. injectable administration efficiency in pediatric patients. Estimated completion date: March 2024.

Summary:

Clinical trial activity remains limited, primarily stressing safety and dosage in vulnerable populations. No high-profile new indications or expanded uses are underway at scale.

How does the current market for MEPHYTON compare with other vitamin K products?

Market Overview (2022-2023)

Segment	Market Size (USD millions)	Key Features	Competitive Position
Pediatric vitamin K (injectable)	150	Used for neonatal hemorrhagic prophylaxis	Market leader, high penetration
Oral vitamin K (adults)	100	Used for anticoagulation advisors	Competes with alternatives (e.g. warfarin)
Hospital/clinical formulation	50	Used in surgery and bleeding management	Niche, primarily clinical settings

Market shares:

• MEPHYTON holds approximately 65% of the injectable pediatric market.
• The oral segment is fragmented, with warfarin and newer anticoagulants posing competition.
• The drug's market growth is driven by increasing neonatal care standards and post-surgical bleeding management protocols.

Market drivers:

• Rising preterm birth rates globally.
• Expanded neonatal intensive care units (NICUs).
• Growing awareness of bleeding risks associated with anticoagulation therapy.

What are the projections for MEPHYTON’s market over the next five years?

Market growth estimates:

• Compound annual growth rate (CAGR) of 3-4% until 2028, driven by:
  • Increased neonatal care investments.
  • Adoption of vitamin K prophylaxis for at-risk infants.
  • Broader use in bleeding management during surgeries and trauma care.

Future demand:

• Neonatal prophylaxis constitutes 70% of the market; expected to expand with improved health care access, especially in emerging markets.
• Anticoagulation-related segments are likely to see slower growth due to competition from oral anticoagulants with better adherence profiles.

Regulatory outlook:

• WHO guidelines endorse vitamin K prophylaxis for newborns; recent updates (2022) emphasize dosage optimization and administration timing.
• No significant regulatory changes affecting MEPHYTON’s approval status expected in the short term.

What are the competitive dynamics shaping MEPHYTON’s market?

Major competitors:

• Konakion (by Merck): Similar formulation, primary competitor in neonatal markets.
• Vitamin K products by Teva, Mylan: Generic injectable formulas.
• Oral anticoagulants (e.g., warfarin, DOACs): Lower-cost alternatives in some indications.

Challenges for MEPHYTON:

• Strong generic competition reduces pricing power.
• Limited new indications slow market expansion.
• Preference shifts toward oral agents for anticoagulation management.

Opportunities:

• Developing combined formulations with other neonatal vitamins.
• Expanding into emerging markets with high neonatal mortality rates.
• Conducting trials to demonstrate benefits over existing therapies.

What are the key takeaways?

• Clinical activity for MEPHYTON is limited but ongoing in neonatal and clinical settings.
• The market remains stable, dominated by established brands with high neonatal prophylaxis usage.
• Growth projections are modest, with a CAGR of around 3-4%, mainly driven by neonatal care needs.
• Competition from generics and oral anticoagulants constrains expansion.
• Opportunities exist based on regional growth and formulation innovations.

FAQs

1. Is MEPHYTON undergoing any new clinical trials for expanding indications?
   No. Current trials focus on dosing, safety, and administration in neonatal and pediatric populations.

2. What is the main driver of MEPHYTON’s market?
   Neonatal hemorrhagic prophylaxis in NICUs.

3. How does MEPHYTON compare with generic competitors?
   It maintains market share through brand recognition and proven efficacy but faces pricing pressures.

4. Are there regulatory challenges ahead for MEPHYTON?
   Not currently; WHO guidelines favor vitamin K prophylaxis, supporting steady use.

5. What is the outlook in emerging markets?
   High potential due to increasing neonatal care access, though competition from cheaper generics is a factor.

References

[1] U.S. Food and Drug Administration. (2022). MEPHYTON (phytonadione injection) prescribing information.
[2] World Health Organization. (2022). Guidance on vitamin K administration in neonates.
[3] MarketResearch.com. (2023). Global vitamin K market report.
[4] ClinicalTrials.gov. (2023). Active and completed clinical trials involving MEPHYTON.